These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34281911)

  • 1.
    Teo MY; Rosenberg JE
    Clin Cancer Res; 2021 Sep; 27(18):4950-4952. PubMed ID: 34281911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity in
    Chu CE; Sjöström M; Egusa EA; Gibb EA; Badura ML; Zhu J; Koshkin VS; Stohr BA; Meng MV; Pruthi RS; Friedlander TW; Lotan Y; Black PC; Porten SP; Feng FY; Chou J
    Clin Cancer Res; 2021 Sep; 27(18):5123-5130. PubMed ID: 34108177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
    Chou J; Trepka K; Sjöström M; Egusa EA; Chu CE; Zhu J; Chan E; Gibb EA; Badura ML; Contreras-Sanz A; Stohr BA; Meng MV; Pruthi RS; Lotan Y; Black PC; Porten SP; Koshkin VS; Friedlander TW; Feng FY
    Eur Urol Oncol; 2022 Dec; 5(6):714-718. PubMed ID: 35216942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of Response to Anti-NECTIN4 Antibody-Drug Conjugate Enfortumab Vedotin in Urothelial Cancer.
    Klümper N; Eckstein M
    Eur Urol Focus; 2024 Mar; 10(2):224-226. PubMed ID: 38631991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance.
    Aggen DH; Chu CE; Rosenberg JE
    Clin Cancer Res; 2023 Apr; 29(8):1377-1380. PubMed ID: 36749325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nectin-4: a Novel Therapeutic Target for Skin Cancers.
    Hashimoto H; Tanaka Y; Murata M; Ito T
    Curr Treat Options Oncol; 2022 Apr; 23(4):578-593. PubMed ID: 35312963
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Klümper N; Tran NK; Zschäbitz S; Hahn O; Büttner T; Roghmann F; Bolenz C; Zengerling F; Schwab C; Nagy D; Toma M; Kristiansen G; Heers H; Ivanyi P; Niegisch G; Grunewald CM; Darr C; Farid A; Schlack K; Abbas M; Aydogdu C; Casuscelli J; Mokry T; Mayr M; Niedersüß-Beke D; Rausch S; Dietrich D; Saal J; Ellinger J; Ritter M; Alajati A; Kuppe C; Meeks J; Vera Badillo FE; Nakauma-González JA; Boormans J; Junker K; Hartmann A; Grünwald V; Hölzel M; Eckstein M
    J Clin Oncol; 2024 Jul; 42(20):2446-2455. PubMed ID: 38657187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intertriginous erythema associated with enfortumab vedotin, a nectin-4-targeting antibody-drug conjugate, in a case with metastatic urothelial cancer: Immunohistochemical evidence for molecular-targeted eruption.
    Hasegawa T; Oyama N; Kasamatsu H; Chino T; Taga M; Hasegawa M
    J Dermatol; 2022 Dec; 49(12):e453-e454. PubMed ID: 36052729
    [No Abstract]   [Full Text] [Related]  

  • 9. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
    Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR
    Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
    Mantia CM; Sonpavde G
    Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nectin-4: a Tumor Cell Target and Status of Inhibitor Development.
    Bouleftour W; Sargos P; Magne N
    Curr Oncol Rep; 2023 Mar; 25(3):181-188. PubMed ID: 36696077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Nectin-4 in Bladder Cancer.
    Cancer Discov; 2017 Aug; 7(8):OF3. PubMed ID: 28634245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma].
    Klümper N; Eckstein M; Kunath F; Heidegger I; Becker C; Rausch S;
    Urologie; 2023 Nov; 62(11):1193-1199. PubMed ID: 37658236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
    Halford Z; Anderson MK; Clark MD
    Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.
    Lacouture ME; Patel AB; Rosenberg JE; O'Donnell PH
    Oncologist; 2022 Mar; 27(3):e223-e232. PubMed ID: 35274723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Anti-Nectin 4: A Promising Tumor Cells Target. A Systematic Review.
    Bouleftour W; Guillot A; Magne N
    Mol Cancer Ther; 2022 Apr; 21(4):493-501. PubMed ID: 35131876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NECTIN4 Expression in Extramammary Paget's Disease: Implication of a New Therapeutic Target.
    Murata M; Ito T; Tanaka Y; Kaku-Ito Y; Furue M
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An iodine‑labelled Antibody-drug conjugate PET probe for noninvasive monitoring of Nectin-4 expression in urothelial carcinoma.
    Ren Y; Liu T; Li S; Ma X; Xia L; Wang P; Guo Q; Yao Y; Hou X; Sheng X; Zhu H; Yang Z
    Int J Pharm; 2024 Feb; 651():123756. PubMed ID: 38160990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.
    Penny CL; Quow K; Rundle CW; Al-Rohil RN; Cardones AR; Kheterpal MK; Fresco AI
    Br J Dermatol; 2022 Jul; 187(1):126-127. PubMed ID: 35048357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enfortumab vedotin in the treatment of urothelial cancers and beyond.
    Wong RL; Yu EY
    Future Oncol; 2022 Sep; 18(27):3067-3084. PubMed ID: 36004667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.